Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05808634 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
A Phase 1 study of Advanced Adenocarcinoma, sponsored by BioAtla.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 168
- Enrollment target
- 9
- Study locations
NCT05808634 is a Phase 1 study of Advanced Adenocarcinoma that is actively recruiting participants, run by BioAtla. The registered enrollment target is 168 participants. The trial reports 9 study locations across 6 states.
The verdict
NCT05808634, a Phase 1 study of Advanced Adenocarcinoma, is actively recruiting participants, sponsored by BioAtla.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 168 participants
- Enrollment target
- 9
- Study locations
Study Summary
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Conditions Studied
Interventions
- DRUG BA3182
Study Locations (9)
California
- UC Irvine - Irvine
- USC Norris Comprehensive Cancer Center - Los Angeles
Illinois
- Northwestern University - Chicago
- University of Illinois - Chicago
Ohio
- The Christ Hospital Cancer Center - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Connecticut
- Yale Cancer Center - New Haven
Michigan
- Karmanos Cancer Institute - Detroit
Washington
- Fred Hutch Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2028-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05808634
The ClinicalTrials.gov registry entry for NCT05808634 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioAtla, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which BA3182 is the first listed.
NCT05808634 reports 9 study locations spanning 6 distinct geographic areas - top geographies include California, Illinois, Ohio.
Frequently Asked Questions
What is clinical trial NCT05808634 about?
NCT05808634 is a clinical study titled "Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.". The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
What is the current status of trial NCT05808634?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 168 participants. The study started on 2023-07-14. Estimated completion is 2028-09-15.
What conditions does trial NCT05808634 study?
This clinical trial studies the following conditions: Advanced Adenocarcinoma.
What interventions are being tested in trial NCT05808634?
The interventions under investigation include: BA3182 (DRUG).
Who is sponsoring clinical trial NCT05808634?
This trial is sponsored by BioAtla, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05808634 being conducted?
This trial has 9 study locations across California, Connecticut, Illinois, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.